Revance Therapeutics logo
Revance Therapeutics RVNC
$ 5.34 2.2%

Quarterly report 2024-Q2
added 08-08-2024

report update icon

Revance Therapeutics Operating Income 2011-2024 | RVNC

Annual Operating Income Revance Therapeutics

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-317 M -342 M -275 M -273 M -164 M -143 M -120 M -88.2 M -72.3 M -52 M -38.2 M -43.2 M -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
-38.2 M -342 M -161 M

Quarterly Operating Income Revance Therapeutics

2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
-34.5 M -46.8 M - -139 M -56.3 M -46.7 M - -77.5 M -57.8 M -62.2 M - -72.7 M -70.3 M -70 M - -77.1 M -57.1 M -61 M -46.2 M -42.5 M -39.1 M -36.6 M -38.4 M -33.6 M -34.9 M -35.7 M - -30.7 M -26.8 M -27.1 M - -17.7 M -24.1 M -19.7 M - -18.8 M -16.6 M -15.2 M - -13.8 M -12.9 M -11.5 M - -8.27 M -11.3 M -9.68 M - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
-8.27 M -139 M -40.6 M